Macular Degeneration Trial, Recruiting (NCT02026843)

Macular Degeneration Trial, Recruiting NCT02026843 Sponsor: Kyungpook National University Hospital Condition: Macular Degeneration

Printed from Voxsanity (voxsanity.com.au) — NCT02026843 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Macular Degeneration

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People aged 20 years or older
People who need eye treatments for a decrease in vision of any level
People who have been diagnosed with certain diseases affecting the back of the eye, including diabetic retinopathy, diseases affecting the blood vessels in the retina, age-related macular degeneration (either the dry or wet type), or degeneration of the retina
People who are scheduled for cataract surgery or a specific type of eye surgery (vitrectomy) for certain non-progressive conditions at the back of the eye

Who may not be able to join:

People under the age of 20 years
People who have already received a particular type of eye injection medication (used to treat abnormal blood vessel growth) before a fluid sample is taken from the eye as part of this trial
People who have not signed the trial's consent form
People who have inflammation or infection inside the eye that requires medication
People who have had a recent eye injury

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 27 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Dong Ho Park, M.D, Kyungpook National University Hospital

Phone: 82-53-420-5813

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT02026843

Sponsor: Kyungpook National University Hospital

Phase: Not Applicable

Status: Recruiting

Condition: Macular Degeneration

Trial contact: 82-53-420-5813

More information: https://clinicaltrials.gov/study/NCT02026843

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People aged 20 years or older
People who need eye treatments for a decrease in vision of any level
People who have been diagnosed with certain diseases affecting the back of the eye, including diabetic retinopathy, diseases affecting the blood vessels in the retina, age-related macular degeneration (either the dry or wet type), or degeneration of the retina
People who are scheduled for cataract surgery or a specific type of eye surgery (vitrectomy) for certain non-progressive conditions at the back of the eye

Who may not be able to join:

People under the age of 20 years
People who have already received a particular type of eye injection medication (used to treat abnormal blood vessel growth) before a fluid sample is taken from the eye as part of this trial
People who have not signed the trial's consent form
People who have inflammation or infection inside the eye that requires medication
People who have had a recent eye injury

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 27 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Kyungpook National University Hospital

Registry

ClinicalTrials.gov

Start date

1 April 2012

Est. completion

1 February 2028

Where this trial is recruiting

🇰🇷 South Korea

Primary endpoints

Biomarkers in ocular fluids

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov